Nature's Sunshine Products, Inc. (NATR) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1157994,
    "name": "Nature's Sunshine Products, Inc.",
    "stock_name": "Nature's Sunshine Products, Inc.",
    "full_name": "Nature's Sunshine Products, Inc.",
    "name_url": "stocks-analysis/nature-s-sunshine-products-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "21.17",
    "chg": 0.32,
    "chgp": "1.53%",
    "dir": 1,
    "prev_price": "20.85",
    "mcapval": "302.27",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2310,
    "indexname": "S&P 500",
    "isin": "US6390271012",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "129.76 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/nature-s-sunshine-products-inc-1157994-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Nature's Sunshine Products, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Metrics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natures-sunshine-products-valuation-grade-changes-from-fair-to-very-expensive-3649048",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NaturesSunshine_valuationdot_3649048.png",
        "date": "2025-10-27 15:50:21",
        "description": "Nature's Sunshine Products, Inc. has recently adjusted its valuation, with its stock price at $14.10. Over the past year, the company has achieved a stock return of 10.76%. Key financial metrics include a P/E ratio of 26 and a return on capital employed of 27.36%, reflecting its position in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Nature's Sunshine Products, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-natures-sunshine-products-inc-overvalued-or-undervalued-3637566",
        "imagepath": "",
        "date": "2025-10-21 12:04:50",
        "description": "As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair. The company is currently overvalued based on its valuation metrics. The P/E ratio stands at 26, which is significantly higher than the peer average of 21.11 for companies like Chromadex Corp. and USANA Health Sciences, Inc., which have P/E ratios of 39.82 and 16.23, respectively. Additionally, the EV to EBITDA ratio of 5.08 is also elevated compared to the peer average of 6.47.\n\nNature's Sunshine Products, Inc. has shown a return of 6.30% over the past year, which is notably lower than the S&P 500's return of 14.08% during the same period, reinforcing the notion that the stock is overvalued in the current market context...."
      },
      {
        "title": "Nature's Sunshine Products, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/natures-sunshine-products-sees-valuation-grade-downgrade-from-attractive-to-fair-3640825",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/NaturesSunshine_valuationdot_3640825.png",
        "date": "2025-10-20 16:37:12",
        "description": "Nature's Sunshine Products, Inc. has recently adjusted its valuation, with its stock price at $14.18. Over the past year, it has returned 6.30%, underperforming the S&P 500. Key metrics include a P/E ratio of 26 and a ROCE of 27.36%, indicating its competitive positioning in the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Is Nature's Sunshine Products, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-natures-sunshine-products-inc-overvalued-or-undervalued-3634434",
        "imagepath": "",
        "date": "2025-10-20 12:22:18",
        "description": "As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 26, which is significantly higher than the peer average of 21.11 for companies like Chromadex Corp. and USANA Health Sciences, Inc., which have P/E ratios of 39.82 and 16.23, respectively. Additionally, the EV to EBITDA ratio of 5.08 suggests that the company is trading at a premium compared to its peers, with LifeVantage Corp. showing a more attractive EV to EBITDA of 8.26.\n\nDespite a one-year return of 6.30%, which is lower than the S&P 500's return of 14.08%, the company's performance over three years at 64.31% is notable but still lags behind the benchmark's 81.19%. Given these factors, Nature's Sunshine Products, Inc. is currently overvalued relativ..."
      },
      {
        "title": "Is Nature's Sunshine Products, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-natures-sunshine-products-inc-overvalued-or-undervalued-3631973",
        "imagepath": "",
        "date": "2025-10-19 11:59:53",
        "description": "As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 26, which is significantly higher than the peer average of 21.11 for comparable companies. Additionally, the EV to EBITDA ratio stands at 5.08, while peers like LifeVantage Corp. have a more favorable ratio of 8.26, indicating that Nature's Sunshine may not be as efficiently valued in comparison to its industry counterparts.\n\nIn terms of performance, Nature's Sunshine has shown a YTD return of -3.27%, lagging behind the S&P 500's return of 13.30%, which further reinforces the notion of overvaluation. The company's ROCE is relatively strong at 27.36%, yet its ROE of 6.38% suggests that shareholder returns are not keeping pace with the cost of equity, adding to the overall valuation concerns...."
      },
      {
        "title": "Is Nature's Sunshine Products, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-natures-sunshine-products-inc-technically-bullish-or-bearish-3545253",
        "imagepath": "",
        "date": "2025-09-20 19:07:23",
        "description": "As of 3 September 2025, the technical trend for Nature's Sunshine Products, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is also bullish, indicating strength over a longer time frame. The daily moving averages are bullish, further reinforcing the bullish stance. However, the monthly RSI is bearish, which presents a divergence in momentum signals. The Bollinger Bands and Dow Theory are both mildly bullish on a weekly and monthly basis, suggesting some upward pressure. \n\nIn terms of performance, the stock has returned 14.26% year-to-date and 23.71% over the past year, outperforming the S&P 500, which has returned 12.22% and 17.14% in the same periods, respectively. Overall, the current technical stance is bullish, with moderate strength driven by the MACD and moving averages...."
      },
      {
        "title": "Is Nature's Sunshine Products, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-natures-sunshine-products-inc-overvalued-or-undervalued-3541973",
        "imagepath": "",
        "date": "2025-09-20 17:41:06",
        "description": "As of 6 August 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from fair to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a P/E ratio of 26, which is notably higher than the industry average, and an EV to EBITDA ratio of 5.08, suggesting that investors are paying a premium compared to its earnings potential. Additionally, the Price to Book Value stands at 1.65, further reinforcing the notion of overvaluation relative to its tangible assets.\n\nIn comparison to its peers, Nature's Sunshine Products, Inc. has a higher P/E ratio than Chromadex Corp. at 39.82 and USANA Health Sciences, Inc. at 16.23, both of which are also classified as very expensive. The company's recent stock performance shows a 1-year return of 23.71%, outperforming the S&P 500's 17.14% return, but this does not mitigate the concerns regarding its curr..."
      }
    ],
    "total": 12,
    "sid": "1157994",
    "stock_news_url": "https://www.marketsmojo.com/news/nature-s-sunshine-products-inc-1157994"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Nature's Sunshine Products, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Metrics

2025-10-27 15:50:21

Nature's Sunshine Products, Inc. has recently adjusted its valuation, with its stock price at $14.10. Over the past year, the company has achieved a stock return of 10.76%. Key financial metrics include a P/E ratio of 26 and a return on capital employed of 27.36%, reflecting its position in the Pharmaceuticals & Biotechnology sector.

Is Nature's Sunshine Products, Inc. overvalued or undervalued?

2025-10-21 12:04:50

As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair. The company is currently overvalued based on its valuation metrics. The P/E ratio stands at 26, which is significantly higher than the peer average of 21.11 for companies like Chromadex Corp. and USANA Health Sciences, Inc., which have P/E ratios of 39.82 and 16.23, respectively. Additionally, the EV to EBITDA ratio of 5.08 is also elevated compared to the peer average of 6.47. Nature's Sunshine Products, Inc. has shown a return of 6.30% over the past year, which is notably lower than the S&P 500's return of 14.08% during the same period, reinforcing the notion that the stock is overvalued in the current market context....

Nature's Sunshine Products, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics

2025-10-20 16:37:12

Nature's Sunshine Products, Inc. has recently adjusted its valuation, with its stock price at $14.18. Over the past year, it has returned 6.30%, underperforming the S&P 500. Key metrics include a P/E ratio of 26 and a ROCE of 27.36%, indicating its competitive positioning in the Pharmaceuticals & Biotechnology sector.

Is Nature's Sunshine Products, Inc. overvalued or undervalued?

2025-10-20 12:22:18

As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair, indicating a shift in its perceived value. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 26, which is significantly higher than the peer average of 21.11 for companies like Chromadex Corp. and USANA Health Sciences, Inc., which have P/E ratios of 39.82 and 16.23, respectively. Additionally, the EV to EBITDA ratio of 5.08 suggests that the company is trading at a premium compared to its peers, with LifeVantage Corp. showing a more attractive EV to EBITDA of 8.26. Despite a one-year return of 6.30%, which is lower than the S&P 500's return of 14.08%, the company's performance over three years at 64.31% is notable but still lags behind the benchmark's 81.19%. Given these factors, Nature's Sunshine Products, Inc. is currently overvalued relativ...

Is Nature's Sunshine Products, Inc. overvalued or undervalued?

2025-10-19 11:59:53

As of 17 October 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from attractive to fair. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 26, which is significantly higher than the peer average of 21.11 for comparable companies. Additionally, the EV to EBITDA ratio stands at 5.08, while peers like LifeVantage Corp. have a more favorable ratio of 8.26, indicating that Nature's Sunshine may not be as efficiently valued in comparison to its industry counterparts. In terms of performance, Nature's Sunshine has shown a YTD return of -3.27%, lagging behind the S&P 500's return of 13.30%, which further reinforces the notion of overvaluation. The company's ROCE is relatively strong at 27.36%, yet its ROE of 6.38% suggests that shareholder returns are not keeping pace with the cost of equity, adding to the overall valuation concerns....

Is Nature's Sunshine Products, Inc. technically bullish or bearish?

2025-09-20 19:07:23

As of 3 September 2025, the technical trend for Nature's Sunshine Products, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supporting the positive trend, while the monthly MACD is also bullish, indicating strength over a longer time frame. The daily moving averages are bullish, further reinforcing the bullish stance. However, the monthly RSI is bearish, which presents a divergence in momentum signals. The Bollinger Bands and Dow Theory are both mildly bullish on a weekly and monthly basis, suggesting some upward pressure. In terms of performance, the stock has returned 14.26% year-to-date and 23.71% over the past year, outperforming the S&P 500, which has returned 12.22% and 17.14% in the same periods, respectively. Overall, the current technical stance is bullish, with moderate strength driven by the MACD and moving averages....

Is Nature's Sunshine Products, Inc. overvalued or undervalued?

2025-09-20 17:41:06

As of 6 August 2025, the valuation grade for Nature's Sunshine Products, Inc. has moved from fair to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a P/E ratio of 26, which is notably higher than the industry average, and an EV to EBITDA ratio of 5.08, suggesting that investors are paying a premium compared to its earnings potential. Additionally, the Price to Book Value stands at 1.65, further reinforcing the notion of overvaluation relative to its tangible assets. In comparison to its peers, Nature's Sunshine Products, Inc. has a higher P/E ratio than Chromadex Corp. at 39.82 and USANA Health Sciences, Inc. at 16.23, both of which are also classified as very expensive. The company's recent stock performance shows a 1-year return of 23.71%, outperforming the S&P 500's 17.14% return, but this does not mitigate the concerns regarding its curr...

View All News